A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation von Kollmann, K, Warsch, W, Gonzalez-Arias, C, Nice, F L, Avezov, E, Milburn, J, Li, J, Dimitropoulou, D, Biddie, S, Wang, M, Poynton, E, Colzani, M, Tijssen, M R, Anand, S, McDermott, U, Huntly, B, Green, T

Volltext

PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis von Berger, A, Hoelbl-Kovacic, A, Bourgeais, J, Hoefling, L, Warsch, W, Grundschober, E, Uras, I Z, Menzl, I, Putz, E M, Hoermann, G, Schuster, C, Fajmann, S, Leitner, E, Kubicek, S, Moriggl, R, Gouilleux, F, Sexl, V

Volltext

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling von Kollmann, K, Nangalia, J, Warsch, W, Quentmeier, H, Bench, A, Boyd, E, Scott, M, Drexler, H G, Green, A R

Volltext

Stat5 is indispensable for the maintenance of bcr/abl‐positive leukaemia von Hoelbl, Andrea, Schuster, Christian, Kovacic, Boris, Zhu, Bingmei, Wickre, Mark, Hoelzl, Maria A., Fajmann, Sabine, Grebien, Florian, Warsch, Wolfgang, Stengl, Gabriele, Hennighausen, Lothar, Poli, Valeria, Beug, Hartmut, Moriggl, Richard, Sexl, Veronika

Volltext

A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation von Kollmann, K, Warsch, W, Gonzalez-Arias, C, Nice, FL, Avezov, E, Milburn, J, Li, J, Dimitropoulou, D, Biddie, S, Wang, M, Poynton, E, Colzani, M, Tijssen, MR, Anand, S, McDermott, U, Huntly, B, Green, T

Volltext bestellen

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling von Kollmann, K, Nangalia, J, Warsch, W, Quentmeier, H, Bench, A, Boyd, E, Scott, M, Drexler, HG, Green, AR

Volltext bestellen

P2.07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab von Park, W., Kwon, D., Saravia, D., Desai, A., Warsch, J., Vargas, F., El Dinali, M., Elias, R., Chae, Y., Kim, D.W., Warsch, S., Ishkanian, A., Ikpeazu, C., Mudad, R., Lopes, G., Jahanzeb, M.

Volltext

P1.07-025 Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab von Park, W., Lopes, G., Kwon, D., Florou, V., Chae, Y.K., Warsch, J., Ishkanian, A., Jahanzeb, M., Mudad, R.

Volltext

P1.07-024 ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors von Park, W., Kwon, D., Desai, A., Florou, V., Saravia, D., Warsch, J., Chae, Y.K., Ishkanian, A., Jahanzeb, M., Mudad, R., Lopes, G.

Volltext